Physician profile
Michael P Dana
NPI 1104160001
$10,095.64
in general payments reported to CMS, 2019-2025
25 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,257 · 2022: $1,676 · 2023: $1,764 · 2024: $1,723 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $3,790.64 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Uswm, LLC | $1,707.97 | 2021-2024 | Lucemyra, Zimhi |
| Abbvie INC. | $1,075.61 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,075.10 | 2021-2025 | Relistor, Trulance |
| Abbott Laboratories | $741.34 | 2024-2025 | Eterna, Proclaim, Octrode |
| Collegium Pharmaceutical, INC. | $439.96 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $200.88 | 2021-2022 | |
| Vertos Medical, INC. | $164.05 | 2024 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $162.32 | 2022 | |
| Virtus Pharmaceuticals LLC | $148.11 | 2023-2025 | Levorphanol Tartrate |
| Lilly USA, LLC | $114.61 | 2022-2023 | Reyvow, Emgality |
| Vertex Pharmaceuticals Incorporated | $84.75 | 2025 | |
| Amgen INC. | $71.15 | 2022 | |
| Nevro Corp. | $52.20 | 2021-2023 | Senza |
| Globus Medical, INC. | $52.06 | 2025 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $35.25 | 2021 | |
| Almatica Pharma LLC | $31.51 | 2021-2022 | |
| Curonix LLC | $30.62 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Hikma Pharmaceuticals USA | $22.78 | 2022 | |
| Tonix Medicines, INC. | $21.70 | 2025 | Tonmya |
| Nalu Medical, INC. | $16.05 | 2021 | |
| Pfizer INC. | $15.88 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.19 | 2025 | |
| Redhill Biopharma INC. | $15.05 | 2022 | |
| Ossur Americas, INC. | $10.86 | 2024 | Miami J |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.